Hyderabad: The original booster shot of vaccines developed.
After two doses were able to produce a strong antibody response and neutralized the omicron and delta variants from SARS-COV-2, a study conducted at Emori University based in Atlanta has been found.
In this study, it was carried out by the Emory Vaccine Center using the neutralization test of life viruses, 100% of the test serum samples showed neutralization of Delta variants and more than 90% of serum samples showed the neutralization of Omicron Bharat Biotech on Wednesday.
As part of the study, which will be published on the Pre-Print Server MEDRXIV immediately, blood serum was collected from 13 Covaxin phase-2 clinical trial participants (conducted by 2020) 28 days after they received their third shot (in 2021) analyzed to neutralize response to both variants.
All participants have received two first doses, 28 days apart and a third dose of six months after the second dose.
This study was sponsored by Bharat Biotech partners for US & Canada, Ocugen Inc.
Bharat Biotech said that this study showed that serum neutralization activity driven by Covaxin was comparable to what had been observed in the MRNA-increase serum vaccine against Omicron, with more than 90%.
Of all individuals are encouraged by covaxin which shows neutralizing antibodies.
“Data from this preliminary analysis shows individuals who accept the Covaxin booster dose have a significant immune response to omicron and delta.
This finding shows that the booster dose has the potential to reduce the severity of the disease and hospitalization,” said Mehul Suthar, assistant professor at Emory University, who leads laboratory analysis.
Bharat Biotech said the latest data adds the body of evidence that the broad spectrum mechanism of the overall actions of the Covid-19 vaccine virus that is not active as Covaxin is a decent option in this growing pandemic.
“Positive neutralization response to the omicron and delta variants, validating our hypothesis against multi-epitop vaccines that produce immune response mediated humoral and cells,” said Chairman of Bharat Biotech & Managing Director Dr.
Krishna Ella, added that with Covaxin, the company has achieved its goal of developing Global Universal Vaccine for Adults and Children.